A low, non-genotoxic, dose (about 1 nM) of ActD has been shown to induce a reversible cytostatic effect in normal proliferating dermal fibroblasts and protect them from the aneuploidy induced by
the aurora kinase inhibitor VX - 680 and the toxic effects of gemcitabine [46, 47].
Rao B, van Leeuwen IM, Higgins M, Campbel J, Thompson AM, Lane DP and Lain S. Evaluation of an Actinomycin D / VX -680
aurora kinase inhibitor combination in p53 - based cyclotherapy.
The first trial to take place as a result of the CDP initiative is a Phase I clinical trial of GlaxoSmithKline's
aurora kinase inhibitor GSK - 1070916A - a promising new drug to treat solid tumours.
Short and long - term tumor cell responses to
Aurora kinase inhibitors.
Not exact matches
A comprehensive review on
Aurora kinase: small molecule
inhibitors and clinical trial studies